Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Net Cash Flow (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Net Cash Flow for 10 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 95.05% to $2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$34.9 million through Dec 2025, down 219.44% year-over-year, with the annual reading at -$34.9 million for FY2025, 219.44% down from the prior year.
  • Net Cash Flow for Q4 2025 was $2.0 million at Rhythm Pharmaceuticals, up from -$83.7 million in the prior quarter.
  • The five-year high for Net Cash Flow was $108.5 million in Q2 2024, with the low at -$113.5 million in Q3 2024.
  • Average Net Cash Flow over 5 years is -$2.3 million, with a median of -$1.2 million recorded in 2023.
  • The sharpest move saw Net Cash Flow tumbled 193.85% in 2023, then surged 1668.92% in 2024.
  • Over 5 years, Net Cash Flow stood at -$33.1 million in 2021, then plummeted by 73.32% to -$57.4 million in 2022, then skyrocketed by 92.48% to -$4.3 million in 2023, then skyrocketed by 1040.74% to $40.6 million in 2024, then tumbled by 95.05% to $2.0 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at $2.0 million, -$83.7 million, and $29.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.